MONTREAL and CHARLOTTE, N.C., April 17, 2024 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive
Milestone Pharmaceuticals (MIST) has released an update. Milestone Pharmaceuticals reveals encouraging results from a Phase 3 study, showing that their investigational drug etripamil enables patients to self-manage recurrent paroxysmal supraventricular
Data from this large safety-trial also published in The Journal of the American College of Cardiology Data from this large safety-trial also published in The Journal of the American College of Cardiology
Milestone Pharmaceuticals announced new clinical data demonstrating real-world application of etripamil, an investigational new drug, for conversion of recurrent paroxysmal supraventricular tachycardia. Conducted in North and South America, this open
MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month. The company will deliver